+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fragment-based Drug Discovery - Global Market Trajectory & Analytics

  • ID: 5140690
  • Report
  • September 2020
  • Region: Global
  • 176 pages
  • Global Industry Analysts, Inc
1 of 2
Global Fragment-based Drug Discovery Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Fragment-based Drug Discovery estimated at US$568 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 10.4% over the period 2020-2027. Fragment Screening Technique, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$644.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fragment Optimization Technique segment is readjusted to a revised 9.7% CAGR for the next 7-year period.

The U. S. Market is Estimated at $168.6 Million, While China is Forecast to Grow at 9.7% CAGR

The Fragment-based Drug Discovery market in the U. S. is estimated at US$168.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$195.6 Million by the year 2027 trailing a CAGR of 9.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.7% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR. We bring years of research experience to this 9th edition of our report. The 176-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:
  • Astex Pharmaceuticals, Inc.
  • Beactica AB
  • Charles River Laboratories International, Inc.
  • Evotec AG
  • Sygnature Discovery Ltd.
Note: Product cover images may vary from those shown
2 of 2
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Global Competitor Market Shares
  • Fragment-based Drug Discovery Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 2: World Historic Review for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 3: World 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • TABLE 4: World Current & Future Analysis for Fragment Screening Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 5: World Historic Review for Fragment Screening Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 6: World 15-Year Perspective for Fragment Screening Technique by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 7: World Current & Future Analysis for Fragment Optimization Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 8: World Historic Review for Fragment Optimization Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 9: World 15-Year Perspective for Fragment Optimization Technique by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 10: World Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 11: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 12: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 13: World Current & Future Analysis for Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 14: World Historic Review for Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 15: World 15-Year Perspective for Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 16: World Current & Future Analysis for Academic and Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 17: World Historic Review for Academic and Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 18: World 15-Year Perspective for Academic and Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
  • Market Facts & Figures
  • US Fragment-based Drug Discovery Market Share (in %) by Company: 2019 & 2025
  • Market Analytics
  • TABLE 19: USA Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 20: USA Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 21: USA 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 22: USA Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 23: USA Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 24: USA 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
CANADA
  • TABLE 25: Canada Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 26: Canada Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 27: Canada 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 28: Canada Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 29: Canada Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 30: Canada 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
JAPAN
  • TABLE 31: Japan Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 32: Japan Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 33: Japan 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 34: Japan Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 35: Japan Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 36: Japan 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
CHINA
  • TABLE 37: China Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 38: China Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 39: China 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 40: China Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 41: China Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 42: China 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
EUROPE
  • Market Facts & Figures
  • European Fragment-based Drug Discovery Market: Competitor Market Share Scenario (in %) for 2019 & 2025
  • Market Analytics
  • TABLE 43: Europe Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 44: Europe Historic Review for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 45: Europe 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • TABLE 46: Europe Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 47: Europe Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 48: Europe 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 49: Europe Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 50: Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 51: Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
FRANCE
  • TABLE 52: France Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 53: France Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 54: France 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 55: France Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 56: France Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 57: France 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
GERMANY
  • TABLE 58: Germany Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 59: Germany Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 60: Germany 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 61: Germany Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 62: Germany Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 63: Germany 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
ITALY
  • TABLE 64: Italy Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 65: Italy Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 66: Italy 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 67: Italy Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 68: Italy Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 69: Italy 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
UNITED KINGDOM
  • TABLE 70: UK Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 71: UK Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 72: UK 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 73: UK Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 74: UK Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 75: UK 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
REST OF EUROPE
  • TABLE 76: Rest of Europe Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 77: Rest of Europe Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 78: Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 79: Rest of Europe Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 80: Rest of Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 81: Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
ASIA-PACIFIC
  • TABLE 82: Asia-Pacific Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 83: Asia-Pacific Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 84: Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 85: Asia-Pacific Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 86: Asia-Pacific Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 87: Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
REST OF WORLD
  • TABLE 88: Rest of World Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 89: Rest of World Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 90: Rest of World 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
  • TABLE 91: Rest of World Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 92: Rest of World Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 93: Rest of World 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 44
Note: Product cover images may vary from those shown
Adroll
adroll